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ABSTRACT
Here, we identify a role for the matrilin-2 (Matn2) extracellular matrix
protein in controlling the early stages of myogenic differentiation.
We observed Matn2 deposition around proliferating, differentiating
and fusing myoblasts in culture and during muscle regeneration in
vivo. Silencing of Matn2 delayed the expression of the Cdk inhibitor
p21 and of the myogenic genes Nfix,MyoD andMyog, explaining the
retarded cell cycle exit and myoblast differentiation. Rescue of Matn2
expression restored differentiation and the expression of p21 and of
the myogenic genes. TGF-b1 inhibited myogenic differentiation at
least in part by repressing Matn2 expression, which inhibited the
onset of a positive-feedback loop whereby Matn2 and Nfix activate
the expression of one another and activate myoblast differentiation.
In vivo, myoblast cell cycle arrest and muscle regeneration was
delayed inMatn22/2 relative to wild-type mice. The expression levels
of Trf3 and myogenic genes were robustly reduced inMatn22/2 fetal
limbs and in differentiating primary myoblast cultures, establishing
Matn2 as a key modulator of the regulatory cascade that initiates
terminal myogenic differentiation. Our data thus identify Matn2 as a
crucial component of a genetic switch that modulates the onset of
tissue repair.
KEY WORDS: Muscle regeneration, Myogenesis, Matn2 shRNA,
TGF-b signaling, BMP signaling, NFI, Trf3
INTRODUCTION
Skeletal muscle regeneration following injury is a multistep
process that restores the tissue architecture by the sequential
activation of multiple signaling pathways (Charge´ and Rudnicki,
2004; Wagers and Conboy, 2005; Yin et al., 2013). The early
degenerative phase involves inflammation, necrosis of the injured
myofibers and degeneration of motor endplates, leading to
denervation. The muscle is then repaired in four regeneration
stages. Repair starts with the activation of satellite cells, which
reside between the basement membrane and the sarcolemma of
muscle fibers, to create a pool of proliferating myoblasts. This is
followed by proliferation, differentiation and maturation stages,
recapitulating the embryonic differentiation steps.
Muscle differentiation is directed by a conserved myogenic
regulatory program during embryonic and fetal development and
muscle regeneration (Charge´ and Rudnicki, 2004; Shi and Garry,
2006). The proliferating myoblasts express the myogenic
regulatory factors (MRFs) Myf5 and MyoD. MyoD initiates a
complex muscle-specific gene expression program that also
involves a network of other transcription factors committing
myogenic precursors to differentiate (Aziz et al., 2010;
Yokoyama and Asahara, 2011). This is accompanied by a
switch of the core transcription machinery, as the MyoD-
dependent activation of the myogenin gene (Myog) requires the
replacement of TFIID with the TRF3–TAF3 complex (Deato and
Tjian, 2007, Deato et al., 2008). The expression of Myog and
Mrf4 in committed myoblasts leads to the upregulation of the Cdk
inhibitor p21 and to irreversible cell cycle exit (Walsh and
Perlman, 1997). Subsequently, overt differentiation starts with the
expression of muscle-specific contractile proteins, and the cells
either fuse to form primitive multinucleated myotubes or merge
with existing myofibers.
The myogenic program is fine-tuned during embryonic and fetal
development and during muscle regeneration by morphogenetic
regulation in response to inductive signals of growth factors (e.g.
FGF, IGF and TGF-b), cytokines and various stimuli from the
extracellular matrix (ECM) (Charge´ and Rudnicki, 2004; Wagers
and Conboy, 2005). TGF-b family members inhibit muscle
differentiation and growth following receptor binding and the
initiation of specific intracellular signals by Smad2 and Smad3
proteins, whereas BMP signaling through Smad1, Smad5 and
Smad8 is a positive regulator of muscle growth (Gardner et al.,
2011; Sartori et al., 2009; Sartori et al., 2013; Winbanks et al.,
2013). Recent data have also implicated specific members of the
nuclear factor I (NFI/Nfi) family of transcription factors in muscle
morphogenesis (Gronostajski, 2000), Nfia being responsible for the
induction of embryonic muscle genes, whereas Nfix activates fetal
genes (Messina et al., 2010).
The ECM has a variety of direct and indirect effects on muscle
differentiation and regeneration. Importantly, the inhibition
of ECM assembly interferes with myogenic differentiation
independently of MRF expression (Osses and Brandan, 2002).
During myoblast differentiation, the fibronectin-rich ECM is
replaced by a laminin-211-containing basement membrane
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deposited by myotubes, which influences myogenic cell
migration and differentiation, myofiber formation and
innervation (Gullberg et al., 1998; Thorsteinsdo´ttir et al., 2011).
A structurally and functionally specialized ECM mediates nerve–
muscle and muscle–tendon contacts at neuromuscular junctions
(NMJ) and myotendinous junctions (MTJ), respectively (Sanes,
2003). Although ample evidence revealed a significant role for
ECM components and cell–ECM interactions at all stages of
muscle development (Thorsteinsdo´ttir et al., 2011), how distinct
ECM components might contribute to skeletal muscle
differentiation and regeneration remains largely unknown.
Microarray analysis has shown an increased expression of
several ECM genes in a mouse model of muscle regeneration,
including the matrilin-2 gene (Matn2) (Goetsch et al., 2003).
Matn2 is the largest member of the matrilin family of multidomain
adaptor proteins (Dea´k et al., 1997; Ma´te´s et al., 2002). Matrilin
oligomers interact with other ECM proteins to form filamentous
networks by connecting collagen fibrils and proteoglycans (Dea´k
et al., 1999; Klatt et al., 2011). Matn2 homo-oligomers are
deposited in varying amounts in the uterus, heart, skeletal and
smooth muscle, in loose and dense connective tissues, and they are
associated with subepithelial basement membranes (Piecha et al.,
1999). Recent studies have demonstrated that Matn2 is required for
peripheral nerve regeneration (Malin et al., 2009), and that Matn2
regulation by the BMP7–Smad signaling pathway can modulate
skin-wound healing (Ichikawa et al., 2008).
Here, we reveal transient Matn2 upregulation during notexin-
induced muscle regeneration in vivo and in differentiating
myoblast cultures. We report delayed myogenic differentiation
from Matn2-silenced myoblast cultures, and a mild dystrophy
with delayed muscle regeneration in Matn22/2 mice. We also
establish that TGF-b can inhibit C2 myoblast differentiation by
decreasing Matn2 expression, and lack of Matn2 delays the onset
of Trf3, Nfix and MRF gene expression. Overall, our data
implicate Matn2 in a signaling network controlling the onset of
the myogenic program, thereby linking ECM–cell interactions to
tissue differentiation and repair.
RESULTS
Transient Matn2 upregulation during skeletal
muscle regeneration
We first assessed a potential role for Matn2 in muscle regeneration
using the well-established model of notexin-induced rat soleus
regeneration. Changes in the injected soleus weight over time
reflected the expected progress of inflammation, necrosis and repair
processes (Fig. 1A). Northern analysis showed marked Matn2
upregulation until 4 days after treatment, followed by a decline in its
expression (Fig. 1B). The transient mRNA accumulation partially
overlapped the expression profiles of the MyoD and Myog
myogenic differentiation markers, but differed from the induction
kinetics of other ECM components, such as biglycan (Bgn) and
syndecan-4 (Sdc4). Quantitative RT-PCR (QRT-PCR) analysis of
Matn2 mRNA revealed a 6.5-fold transient activation that followed
the peak of expression of MyoD and closely paralleled that of Myog
(Fig. 1C). The Matn2 mRNA level increased similarly to that of Fak
(also known as Ptk2), a common integrin target (Goody and Henry,
2010). We concluded that Matn2 is upregulated during the
regeneration phase, which involves myoblast proliferation and
differentiation to myocytes, early myotubes and myofibers, whereas
it is downregulated during myofiber maturation.
Immunoblots revealed predominantly Matn2 oligomers of low
signal intensity in the untreated control, whereas mainly Matn2
Fig. 1. Marker gene expression during rat soleus regeneration.
(A) Weight changes during notexin-induced regeneration. Data show the
mean6s.e.m. (n§3); **P,0.01. (B,C) Kinetic changes in marker gene
expression were aligned with the stage of regeneration (Shi and Garry,
2006), based on histological analysis of H&E-stained sections (Fig. 2A).
Pooled total RNA derived from control and regenerating samples (n53)
was subjected to northern hybridization (B) and QRT-PCR using the
SYBR green protocol (C). For QRT-PCR, relative expression levels
normalized to those of the untreated control (DDCt) are shown.
(D) Immunoblot analysis of Matn2 expression during regeneration. t, trimer;
d, dimer; m, monomer.
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monomers were observed during regeneration. The elevated
monomer signal at 1 day post-injury likely resulted from the
proteolytic cleavage of oligomers that might be poorly recognized
by the antibody in the control (Fig. 1D). The amount of
monomers decreased after day 4, whereas the oligomer
formation was restored.
Immunolocalization of Matn2 in regenerating muscles
To reveal which cell types might express Matn2, we compared the
localization of Matn2 with that of specific markers during known
stages of muscle regeneration (Charge´ and Rudnicki, 2004; Gorbe
et al., 2005; Shi and Garry, 2006), which were determined by
hematoxylin and eosin (H&E) staining of muscle sections (Fig. 2;
supplementary material Fig. S1). Unlike the weak Matn2 staining
of the endomysium relative to nerves and blood vessels in the
untreated muscle, an intense Matn2 signal was observed at the
periphery of necrotic myofibers and in the interstitial tissue at day 1
post-injury (Fig. 2A–D; supplementary material Fig. S1A,D). This
further implied a proteolytic release of Matn2 epitopes from
oligomers and ECM linkages in the old endomysium, thereby
resulting in better recognition by the antibody. Using myogenic,
basement membrane and inflammatory cell markers, we observed
Matn2 deposition around MyoD-, Myog- and Lama2-positive
proliferating and differentiating myoblasts on day 2, but not around
granulocytes and macrophages (Fig. 2B–F; supplementary material
Fig. S1B,C; data not shown). Matn2 colocalized with laminin
in the basement membrane surrounding desmin-positive fusing
myoblasts, myotubes and myoblasts merging with newly formed
myofibers (Fig. 2B–D,F), implying that both proteins can
participate in the ECM assembly that assists myoblast
differentiation and fusion. Matn2 signal was also relatively strong
in the endomysium, but not in the laminin-containing basement
membrane of recently formed myofibers strongly stained for
desmin (Fig. 2B–D) but still containing central nuclei on day 14
(arrow, Fig. 2A). Matn2 expression decreased during myofiber
maturation, but it was more intense and broader in the endomysium
and interstitial tissue on day 14 than in the control (Fig. 2B–D).
The Matn2 signal partially overlapped those of fibronectin and
collagen-1 throughout the regeneration process (supplementary
material Fig. S1D).
While keeping the muscle nerves intact, notexin treatment
destroys their motor endplates. Unlike myoblast proliferation,
myofiber maturation depends on nerve signals (Grubb et al.,
1991; Sesodia and Cullen, 1991). Matn2 deposition was also
highly elevated around nerves and the NMJs that were re-
established in large number between the recently formed
myofibers and nerve terminals at days 4–7 (Fig. 2B,G). Double
staining showed intense Matn2 deposition at re-established NMJs,
specifically in close proximity to acetylcholine receptors in the
postsynaptic membrane (Fig. 2H). The Matn2 signal extended to
the synaptic membrane and the presynaptic area around the cap
formed by terminal Schwann cells (TSCs) (Fig. 2I). The observed
deposition of Matn2 around myoblasts, myotubes, newly formed
myofibers and NMJs suggested a role for Matn2 in the early steps
of myogenic differentiation and reinnervation.
Transient Matn2 activation in differentiating C2 myoblasts
To provide independent evidence that myoblasts can deposit a
Matn2-rich ECM, we next monitored Matn2 expression in C2
myoblasts cultured in differentiation medium, as this cell line model
was reported to faithfully mimic fetal muscle differentiation (Biressi
et al., 2007; Halevy et al., 1995; Messina et al., 2010; Montarras
et al., 1996). Polygonal C2 myoblasts proliferating in growth
medium (day 0) showed Matn2, laminin and fibronectin deposition,
but only traces of desmin and no a-actinin immunofluorescence
(Fig. 3A–D). In differentiation medium, myoblasts differentiated to
spindle-shaped myocytes and myotubes exhibiting intense desmin,
Matn2, laminin and fibronectin signal at day 2, followed by the
formation of aligned multinucleated myotube-like structures with
high desmin and laminin staining by day 6 (Fig. 3B,D). Long
spindle-shaped cells staining for sarcomeric a-actinin appeared in
the culture from day 2 (Fig. 3C).
Whereas Matn2 was deposited by proliferating myoblasts in fine
granules on day 0, it formed laminin and fibronectin-connected
filaments surrounding fusing myoblasts and primary myotubes
from day 2 (Fig. 3D,E). The Matn2 filaments appeared to be
involved in cell attachment (Fig. 3E), being incorporated into an
extensive filamentous network closely associated with fibronectin
and connected to the laminin-containing basement membrane
around multinucleated myotubes by day 6 (Fig. 3D).
The Matn2 mRNA level in differentiating myoblasts also
exhibited a transient increase with a peak at day 2, thus
overlapping the transient accumulation of MyoD and Myog
mRNAs (Fig. 3F). The amount of Matn2 trimers, dimers and
monomers secreted into the medium also increased transiently to
a maximum on days 2–4 in differentiation medium (Fig. 3G),
concomitantly with the appearance of myotubes. These data thus
confirmed the deposition of Matn2 by proliferating myoblasts and
during the early steps of C2 myoblast differentiation.
Matn2 is required for C2 myoblast differentiation
To address whether Matn2 might be needed for myogenic
differentiation, we silenced its expression in C2 myoblasts using
an efficient transposon-based short-hairpin (sh)RNA expression
system (Kaufman et al., 2005). Independent stable-knockdown
lines constitutively expressing either Matn2-targeting shRNA
(lines sh3, sh4 and sh7) or the control vector (line Ctrl) were
established and tested for differentiation and the expression of
marker genes. Matn2 mRNA levels were successfully reduced
in lines sh7, sh4 and sh3, with expression levels ranging from
52.2% to 17.6% of that of the control line, as determined by
QRT-PCR (Fig. 4A); expression of the Matn2 protein decreased
similarly (supplementary material Fig. S2B). Prior to
differentiation, the Matn2-silenced cells were morphologically
identical to control myoblasts (data not shown) and proliferated at
similar rates, as based on their mitochondrial activity (Fig. 4B)
and on cell count data (data not shown). Upon culturing in
differentiation medium, myotube formation was delayed by 2–
3 days and the frequency of sarcomeric a-actinin-positive
myocytes and their fusion to multinucleated myotubes was
highly reduced in Matn2-silenced myoblast cultures relative to
that of control cultures (supplementary material Fig. S2A,B). The
primary myotube frequency, fusion index and differentiation
index decreased in correlation with the reduction in Matn2
immunofluorescence and mRNA expression of the cultures
(Fig. 4A,C; supplementary material Fig. S2B). Thus, silencing
Matn2 expression delayed both the differentiation and fusion of
myoblasts.
Delayed myoblast differentiation was further supported by
comparative QRT-PCR, which revealed the most robust changes
in myogenic gene expression between the control line and the sh4
and sh3 silenced cell lines in repeated differentiation experiments
(supplementary material Fig. S2C; data not shown). Thus, Matn2
silencing interfered with the transient activation of MyoD and
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Fig. 2. Progress of morphological changes and Matn2 deposition during rat soleus regeneration. (A) H&E staining of transverse paraffin sections. The
star indicates inflammatory cells. (B–D) Immunofluorescence of serial cryosections for Matn2 (B–D) and laminin a2 (Lama2) (C) or desmin (Des) (D). The
star indicates interstitial tissue (B). (E) Deposition of Matn2 around MyoD- and Myog-expressing proliferating and differentiating myoblasts at day 2 post-injury.
(F) Matn2 deposition in the interstitial tissue (star) and around myoblasts (arrowhead) differentiating and fusing within the basement membrane, which is also
stained for laminin-111 (Lam, arrow), at 2 days post-injury. (G–I) Localization of Matn2 to NMJs on day 4. Note the strong Matn2 signal at the newly
established NMJs, as visualized by Rhodamine-labeled a-bungarotoxin (BTX) staining of acetylcholine receptors (G, arrowhead). There is partial overlap
between Matn2 and a-bungarotoxin signals at NMJs (H, arrows). TSCs visualized by GFAP staining are covered by Matn2-rich ECM at the NMJ (I). Insets
show a section of the main image at higher magnification (A,B). Single-channel images of the entire image (C,D,F) or the outlined area (G) are shown beneath
the main image. cnf, centrally nucleated myofiber; em, endomysium; mb, myoblast; mf, myofiber; mt, myotube; n, nerve; nmf, necrotic myofiber; pm,
perimysium; v, blood vessel.
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Myog, as well as with the progressive increase in the p21 mRNA
level observed in control myoblasts, readily explaining the
delayed commitment, cell cycle exit and differentiation of the
silenced cell lines. Matn2 silencing also hampered the activation
of Fak, a gene encoding a modulator of cell–ECM contacts, and
the transient rise in the expression of ECM genes (e.g. Lama2,
Col6a1 and Sdc4), the expression of which paralleled that of
Matn2 in the control line. As no marked alteration was seen for
the unrelated control p53 and Col1a1 mRNAs, this indicated that
Matn2 silencing exerts a specific effect on the expression of MRF
and differentiation-related genes.
Next, we tested whether rescuing Matn2 synthesis in a silenced
cell line can restore the proper timing of myogenic
differentiation. To this end, we mutated the sequence targeted
by the shRNA in the mouse Matn2 cDNA in the third positions of
codons, thereby preserving its protein-coding capacity while
disrupting the shRNA target site (Fig. 4D). Then, we introduced a
constitutive expression vector harboring the modified cDNA into
Matn2-silenced sh3 myoblasts and selected for pools of
puromycin-resistant stable clones (sh3-res2) for further analyses
(Fig. 4E–I). The Matn2 levels of the complemented sh3-res2
myoblasts reached those of the control line in both the
conditioned differentiation medium and in the filamentous
ECM extracts (Fig. 4E,F). As expected, given the use of the
constitutive CMV promoter to drive Matn2 expression, a decrease
in Matn2 level was not noted in the sh3-res2 culture at day 6 in
differentiation medium. During differentiation, a-actinin-positive
myotubes appeared at a frequency similar to that of the control
line (Fig. 4G,H), and the myoblast proliferation rates were similar
(data not shown). Bmp signaling, which controls muscle growth
Fig. 3. Matn2 expression in proliferating and differentiating C2 myoblasts. (A–E) Phase-contrast images (A) and double immunofluorescence for Matn2
and other markers (B–E) of myoblast cultures differentiating to multinucleated myotubes (mmt) in differentiation medium. Desmin (B) and a-actinin staining
(C) demonstrates the progress of differentiation. mb, myoblast; mt, myotube. (D) Partial colocalization of Matn2 with laminin-111 (Lam) and fibronectin (Fn).
(E) Granular Matn2 deposition (asterisk) by proliferating myoblasts (day 0). Arrows mark the vinculin-positive focal adhesions left behind upon cell movement.
Matn2 filaments are linked to the cells at paxillin-positive focal adhesions (arrowhead) on day 4. Separate images for Matn2 alone or for other markers and
DAPI are shown above the main images in B, D and E. The area outlined in white in E is shown at higher magnification below the main image. (F) Comparison of
mRNA levels for Matn2 and MRFs by northern hybridization. (G) Immunoblot analysis of Matn2 that was secreted daily into the differentiation medium. t,
trimer; d, dimer; m, monomer.
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Fig. 4. The effect ofMatn2 silencing and rescue on differentiation andmarker gene expression of C2myoblasts. (A)Matn2mRNA levels were measured by
QRT-PCR in proliferating C2 cell lines stably expressing Matn2 shRNA (sh7, sh4 and sh3) or the control vector (Ctrl). (B) The proliferation rate of the control and
silenced cell lines was determined by using the MTS assay in growth medium. (C) Primary myotube frequency, fusion index and differentiation index of the cell
lines on day 5 in differentiation medium. (D) Coding sequences are depicted for the Matn2 shRNA, the endogenous Matn2 and the rescue cDNA clone, which is
resistant to shRNA interference. Immunoblotting was performed on the conditioned differentiation medium (E) and cell lysates (F) from the silenced sh3,
rescued sh3-res2 and Ctrl myoblast cultures. Only the trimeric form of Matn2 is shown. Cytoskeletal b-actin served as a loading control. (G) Immunofluorescence for
a-actinin-positive cells in the cultures. (H) Differentiation index as determined on day 5. (I) QRT-PCR analysis of relative gene expression (Rel. exp.) in the same
cultures using TaqMan probes. Marker mRNA levels are given as fold values relative to the Hprt mRNA level. Data show the mean6s.e.m. (A–C, H). ***P,0.001,
compared with control (n53–5). For E–G and I, representative data from three independent experiments are shown.
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(Sartori et al., 2013; Winbanks et al., 2013), yielded comparable
effects, as judged from the similar phosphorylation of Smad1/5/8
(supplementary material Fig. S3B). Smad4 expression was not
altered, but large differences were seen in the expression of p21
(Fig. 4F). Unlike its low level in sh3 cells, p21 expression could
already be detected at day 2 in the rescued culture, and it
increased steadily to reach a level of expression similar to that of
the control, but at an earlier time-point. Desmin and a-actin
expression was also rescued in the sh3-res2 cultures. As Matn2
silencing also altered the phosphorylation of Fak and p42/44 (also
known as Erk1/2) (supplementary material Fig. S3B,C), it is
likely to modulate several signaling pathways. Thus, the
decreased expression of Matn2 hampered the induction of p21
and overt differentiation, despite the increased expression of the
TGF-b signaling intermediate Smad4, and this effect could be
reversed by restoring Matn2 expression and its deposition in the
ECM. QRT-PCR confirmed the restoration of muscle-specific
gene expression in differentiating Matn2-rescued myoblasts
(Fig. 4I), and the increase in the Matn2 level was paralleled by
the increased expression of MyoD and Myog and of the adult
myosin heavy chain (Myh1) mRNAs.
The finding that Matn2 expression might regulate myoblast
differentiation prompted us to assess the regulation of
transcription factors that are possibly involved in the onset of
Matn2 expression. Nfi proteins have been implicated in the
control of adult stem cells and tissue regeneration in connection
with TGF-b signaling (Plasari et al., 2009; Plasari et al., 2010).
Nfix has been shown to drive a transcriptional switch from
embryonic to fetal myogenesis in vivo and in C2 culture by
suppressing the effect of Nfia and activating fetal muscle genes
(Messina et al., 2010). When monitoring Nfix or Nfia expression
during myogenesis, we observed that Nfix and, to lesser degree,
Nfia were indeed activated in both the differentiating control and
Matn2-rescued myoblasts, but were either silent or only
expressed at low levels in the silenced cells (Fig. 4I). The Nfix,
Nfia and Matn2 mRNAs accumulated with similar kinetics in
Matn2-expressing cells, and their expression preceded myogenic
gene expression. This suggested that Matn2 might control
myogenic differentiation by regulating the expression of Nfi
proteins. Interestingly, a rise in Matn2 expression above a
threshold level was likely needed to turn on the expression of Nfix
and of the downstream Myh1 and Mstn genes in sh3-res2 cultures
(compare Fig. 4I and supplementary material Fig. S3A), implying
that Matn2 and Nfix might be part of a genetic switch driving an
all-or-none differentiation response.
TGF-b signaling represses Matn2 expression and
myoblast differentiation
Matn2 has been shown to be regulated by Smad signaling in other
cell types (Ichikawa et al., 2008), and TGF-b and Smad2/3
signaling is known to inhibit myogenic differentiation and muscle
growth (Gardner et al., 2011; Sartori et al., 2009; Winbanks et al.,
2012). Thus, we next assessed whether Matn2 and TGF-b
signaling might regulate one another in differentiating myoblasts.
As expected, the addition of TGF-b1 to differentiation medium
inhibited the differentiation of the control line and hampered
Smad1/5/8 phosphorylation (Fig. 5A,B). However, TGF-b1 had
only a small delaying effect on the differentiation of sh3
myoblasts, whereas Matn2 expression rescue restored the
inhibition (Fig. 5A). TGF-b1 robustly inhibited the increase in
Matn2 mRNA levels, and it consistently reduced the deposition of
Matn2 in the ECM from the control and sh3-res2 cultures,
especially during the early stages of differentiation (12–36 h,
Fig. 5C,D). Similarly, TGF-b1 further reduced the low levels of
Matn2 mRNA and of high-molecular-mass Matn2 complexes
from differentiating sh3 myoblasts. Interestingly, the decrease
in the p21, Trf3, Nfix and Nfia mRNA levels paralleled
the decreased Matn2 expression, whereas both TGF-b1 and
differentiation medium strongly induced Smad4 expression
(Fig. 5C,D). The most prominent decrease in p21 expression
was obtained in the TGF-b1-treated sh3 cells, which displayed
the lowest Matn2 levels and the highest Smad4 levels. As Trf3 is
needed for the transition of the basal transcription machinery and
for MyoD-dependent Myog induction during myogenesis (Deato
and Tjian, 2007; Deato et al., 2008), and both Matn2 silencing
and TGF-b1 compromised Trf3 induction in differentiation
medium, our data suggest that low extracellular Matn2 and
TGF-b1 signaling act in concert to inhibit p21 expression and
myoblast differentiation. Accordingly, TGF-b1 abolished the
induction of Trf3 and subsequently reduced MyoD and Myog
induction upon differentiation of Matn2-expressing control and
sh3-res2 myoblasts, whereas TGF-b1 further reduced the silenced
Matn2 level and fully abrogated the expression of the two MRFs
from sh3 cells (Fig. 5D). Overall, we concluded that Matn2 can
activate Trf3 and p21 expression and myogenic differentiation,
and the TGF-b1–Smad-pathway-mediated inhibition of
differentiation might stem in part from the inhibition of Matn2,
Trf3, p21 and perhaps also Nfix expression.
Matn2 is activated by the myogenic Nfix and MyoD regulators
Based on the observation that Matn2 and Nfix mRNAs accumulated
with comparable kinetics during early myogenesis and on the
previous finding that Nfix can promote myogenesis, we next
assessed whether Nfix might directly regulate Matn2 expression. As
Matn2 is transcribed from two promoters (Ma´te´s et al., 2002), we
tested which of the upstream (Pu) or downstream promoter (Pd) can
direct the transient gene activation during muscle regeneration and
myoblast differentiation (Fig. 6A–C). Transcription from Pu did not
change markedly in either case. By contrast, the Pd-specific
transcript was reproducibly upregulated between 6 h and 4 days
after soleus injury, followed by a decline during myofiber formation
(Fig. 6B, arrow). Consistently, transcription from Pd increased
transiently during the early stages of C2 myoblast differentiation,
but ceased during the formation of multinucleated myotubes
(Fig. 6C, arrow).
Sequence analysis revealed putative NFI- and MyoD-binding
motifs in the Pd region, including potentially overlapping binding
sites for both proteins (Fig. 6D). Electrophoretic mobility shift
assay (EMSA) showed MyoD binding to the Pd212/+15 DNA
element near the transcription start site, and this binding was
abolished by mutation in the MyoD motif (Mdm1) (Fig. 6D,F).
Both MyoD and the CTF1 NFI isoform bound weakly to the
Pd2135/2107 upstream element, and point mutations disrupting
both consensus motifs (NfMdm1) abolished this interaction. Low
amounts of MyoD inhibited NFI binding, indicating that the two
proteins can compete for binding to the distal overlapping sites.
The Mdm1 mutation moderately increased the Pd activity in C2
myoblasts (Fig. 6E,G). An NFI-contact-point mutation (Nfm1) in
the overlapping NFI and MyoD sites was strongly inhibitory,
whereas the NfMdm1 mutation that eliminated the binding of
both proteins increased the promoter activity. In C2 myoblasts,
MyoD expression decreased whereas Nfix expression increased
the Pd-driven luciferase activity (Fig. 6H). Nfix expression in
COS-7 cells confirmed that it acts as an activator of the Pd, as did
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the Nfia and Nfib species, whereas MyoD acted as a repressor
(Fig. 6I,J). Coexpression of MyoD and Nfix did not relieve
MyoD-mediated repression of the Pd, indicating that MyoD can
fully block the activation by Nfix, in agreement with their
competitive binding in EMSA assays and with MyoD high-
affinity binding to a site overlapping Matn2 transcription
Fig. 5. The effect of TGF-b1 on the differentiation of Ctrl, sh3 and sh3-res2 myoblasts. Cells were cultured in differentiation medium with and without TGF-
b1. (A) Immunofluorescent staining for a-actinin on day 3 of differentiation. (B) Smad1/5/8 phosphorylation during the differentiation of the control cell line
was assessed by immunoblotting. (C) Western blot analysis of three pooled samples for Matn2, Smad4 and p21 expression. Cytoskeletal b-actin served
as a loading control. t, trimer; d, dimer; m, monomer. (D) QRT-PCR of three pooled parallel cultures using the SYBR green protocol.
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initiation site. The Matn2 promoter also harbors putative Smad
sites that might mediate the TGF-b1 inhibitory effect (Fig. 6D).
As BMP7 was reported to activate MATN2 and its promoter in
other cells (Ichikawa et al., 2008), we also assessed the activation
of the Matn2 promoter by BMP7. We found that BMP7 led to a
threefold increase in Pd activity and increased its transactivation
by low doses of Nfic and Nfix (Fig. 6K).
Overall, we conclude that a transient increase in Matn2 Pd
activity results from the upregulation of NFI species in early
myogenesis, whereas the expression of MyoD at later stages of
Fig. 6. See next page for legend.
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differentiation might repress Matn2 expression. A mechanism
involving Matn2 activation at the onset of the myogenic program,
together with the finding that Matn2 and Nfix each activate the
expression of the other during early myoblast differentiation
(Figs 4–6), explains the transient upregulation of Matn2 during
myoblast differentiation and muscle regeneration. The initial
increase in Matn2 expression at day 1 is expected to lead to an
increase in Nfix and Nfia expression (Fig. 4I), which would
further increase Matn2 expression. This positive-feedback
regulatory loop would ensure high expression of Nfix, Nfia and
Matn2 at early differentiation stages, whereas the later increase in
MyoD expression would contribute to the downregulation of
Matn2 expression in a negative-feedback loop during terminal
myogenic differentiation.
Matn2 deficiency impairs proper muscle regeneration in vivo
Similarly to rat muscles (Fig. 2A,G), high Matn2 signal was
observed in nerves, tendons and MTJs, and the signal intensity in
the epi-, peri- and endomysium was lower in adults than newborn
mice (supplementary material Fig. S4A–G). To further establish
the function of Matn2 in myogenesis in vivo, we next compared the
regeneration of tibialis anterior muscle following notexin-induced
injury in Matn2 knockout (Matn22/2) and wild-type mice (Fig. 7).
Significant differences were seen in the muscle weight to body
weight ratio at days 3–5 (Fig. 7A). The average myofiber cross-
sectional area (CSA) did not differ significantly, but the myofiber
size was more heterogeneous and fiber splitting occurred more
frequently in Matn22/2 than in wild-type mice (Fig. 7B–D). The
incidence of centrally nucleated myofibers increased fivefold
in the untreated Matn22/2 muscles, and the proportion of central
myonuclei was also significantly higher in both the untreated and
regenerating muscles of Matn22/2 mice than in those of wild-
type mice, indicating a mild muscular dystrophy (Fig. 7E,F;
supplementary material Fig. S4H). Consistently, decreased desmin
staining and an increased number of Ki67+ and Ki67+MyoD+
cells were observed in Matn2-deficient mice at days 3 and 5 of
regeneration, respectively (Fig. 7G,H). Immunofluorescence
revealed a delayed regeneration in Matn2-deficient mice, as
indicated by the delayed desmin staining and the large number of
myoblasts still detected inside the basement membrane of the
necrotized and regenerating Matn22/2 muscle fibers at days 5 and
7 post-injury (Fig. 7I). At late stages of regeneration, signs of mild
muscular dystrophy were seen in Matn22/2 mice, including
necrosis, inflammation and increased fibrosis (Fig. 7I; Fig. 8A;
supplementary material Fig. S4H). Central myonuclei and
myofiber splitting also occurred more frequently, whereas
fibrosis was not more pronounced in older Matn22/2 than in
wild-type animals (supplementary material Fig. S4I,J).
Next, we tested the effect of Matn2 deficiency on the muscle-
specific gene expression in fetal limbs and myoblasts derived
from newborn mice. Remarkably, QRT-PCR analysis revealed a
361-fold drop in Trf3 expression, followed by robust
downregulation in the expression of Nfix, Nfia, Bmp7 and late
differentiation markers (Eno, Myh1) in Matn22/2 fetal limbs at
embryonic day 16.5 (E16.5) (Table 1). Matn2 deficiency also
significantly decreased the expression of the MyoD, Fak and Taf3
myogenesis regulators. Because an Nfix-directed switch from
embryonic to fetal myogenesis takes place between E14.5 and
E17.5 (Messina et al., 2010), along with the switch of the TFIID
to a Trf3–Taf3-containing complex (Deato and Tjian, 2007), our
data imply that Matn2 deficiency impairs the global switch
towards terminal muscle differentiation by robustly preventing
the induction of myogenic regulators, such as Trf3 and Nfix.
The regulatory cascade induced by Matn2 is elicited by the
myoblasts themselves, as the expression of Trf3, Taf3, Bmp7,
MyoD, Fak, Nfic, Nfix and Itga5 were all decreased in Matn22/2
versus Matn2+/+ cultured myoblasts (Table 1). When the kinetics
of primary myoblast differentiation were assessed in
differentiation medium, a transient 160-fold activation of Matn2
expression was accompanied by a 28–50-fold transient induction
of Tfr3, Taf3, Nfix, Nfic, Nfia and Bmp7 and by elevated
expression of Itga and Fak in differentiating Matn2+/+ myoblasts
(Fig. 8B). Interestingly, after a 50–100-fold activation on day 2,
the levels of MyoD and Myog peaked at day 7, following the
earlier activation of p21 and Myh1 with a kinetics similar to those
of Trf3, Taf3 and Nfi.
By contrast, in the absence of Matn2, the expression of Trf3,
Taf3, MyoD, Myog and other myogenic marker genes was not
induced (Fig. 8B). Thus, Matn2 deficiency interfered with the
transient activation of Nfix and Nfia regulating fetal and embryonic
muscle genes, and it also prevented the induction of the Bmp7 and
Nfic intermediates of the BMP/TGF-b signaling pathways.
Decreased Itga5 and Fak expression in Matn22/2 myoblasts and
during their differentiation, respectively, indicated that Matn2
deficiency can also affect integrin signaling (Fig. 8C,D). p42
(Erk2) phosphorylation was also inhibited in Matn22/2 mice
(supplementary material Fig. S3C).
Taken together, our data indicate that the myoblast-secreted
Matn2 is needed for Trf3 and Taf3 induction during
differentiation, thereby selectively turning on the cascade of
MRFs and Nfix, the activator of fetal muscle genes. Thus, we
conclude that Matn2 acts as a key and early regulator of fetal
myogenic differentiation, and that its transient activation and the
feedback regulatory loops it forms with Nfix and MyoD might
drive proper and timely BMP7 and integrin a5 signaling during
the early stages of muscle differentiation.
DISCUSSION
Numerous studies of normal and myopathic muscles have
underlined the crucial dependence of muscle development and
function upon proper cell–ECM interactions. However, how this
interaction can contribute to myogenic differentiation has
remained poorly understood. This study uncovers a crucial role
Fig. 6. Regulation of theMatn2 promoter by MyoD and Nfi. (A) Schematic
illustrating the exons E1–E3, the two alternative promoters and the Matn2
transcripts. Primer pairs specific for Pu and Pd and for intronic control (IC) are
depicted (arrows), and have been described previously (Ma´te´s et al., 2002).
Semi-quantitative RT-PCR analysis using Pu- and Pd-specific and control
primer pairs during soleus regeneration (B) and C2 myoblast differentiation
(C). (D) Nucleotide sequences showing the putative factor-binding sites in the
Pd region and in the wild-type (WT) and mutant versions of DNA elements
Pd212/+15 and Pd2135/2107. Mutated nucleotides are shown in lower case.
(E) Structure of the Pd-luciferase fusion construct. (F) The binding of purified
GST (glutathione S-transferase), GST–MyoD and GST–CTF1 (NFIC isoform)
to the wild-type and mutant Pd212/+15 and Pd2135/2107 DNA elements
was determined in EMSA. F, free probe. (G) The effect of the NFI and MyoD
motif mutations shown in D on the Pd activity of Pd(2342)Luc in C2 myoblasts.
(H–K) The effect of forced expression of NFI proteins and MyoD from the
indicated amounts of expression plasmids (pFNfi and pFMyoD) on the
luciferase activity of Pd(2342)Luc in C2 myoblasts and COS-7 cells. In COS-7
cells, NFI proteins can increase Pd activity (I), whereas MyoD alone or upon
coexpression with Nfix can repress it (J). Bmp7 can increase Pd activity and its
dose-dependent activation by Nfic and Nfix (K). Data represent the
mean6s.e.m.; *P,0.05, **P,0.01, ***P,0.001 [relative to Pd(2342)Luc],
#P,0.05, ###P,0.001 (as indicated).
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for the ECM component Matn2 in skeletal muscle differentiation
and regeneration. We find that a transient upregulation of Matn2
followed by Matn2 deposition around proliferating, differentiating
and fusing myoblasts is required for timely myoblast
differentiation in culture and during muscle regeneration in vivo.
This conclusion is supported by the finding that silencing or
knockout of Matn2 delays myogenic differentiation from cultured
myoblasts by inhibiting the activation of MRFs, p21, Nfix and other
Fig. 7. See next page for legend.
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myogenesis-related genes. Conversely, rescuing Matn2 expression
in Matn2-silenced myoblasts attenuated the delay in differentiation
and restored the induction of Nfix and myogenic marker genes.
The muscle regeneration delay in Matn22/2 mice was
accompanied by a lack of Trf3 and Taf3 induction in vivo,
thereby compromising the global transition of the core promoter
complex and the activation of MRF (MyoD, Myog), p21 and
muscle-specific genes (Myh1). In addition to identifying Matn2 as
an upstream global modulator of myogenic differentiation, these
data further support the proposal that the Trf3–Taf3 complex
plays a pivotal role in terminal muscle differentiation by
specifically activating a subset of myogenic marker genes while
inhibiting many others (Deato and Tjian, 2007; Deato et al., 2008;
Jones, 2007). Matn2 deficiency also interferes with the activation
of Nfix, which defines the fetal myogenic cell fate (Messina et al.,
2010). This correlates well with the previous in vivo observation
of Matn2 fetal-specific expression during the myoblast–myotube
transition (Blais et al., 2005; Biressi et al., 2007; Mourikis et al.,
2012). Matn2 might thus induce muscle-specific gene expression
changes by coordinating various signaling pathways, as Matn2
deficiency also impairs the activation of genes involved in the
Bmp7 and integrin a5 signaling pathways during differentiation.
Based on the present work and data available from the
literature, we propose a hypothesis for the Matn2-dependent
timely onset of myogenic differentiation (Fig. 8E). Our data show
that Matn2 can modify integrin and other (e.g. Fak, Erk2)
signaling pathways and that Matn2 deficiency dramatically
impairs the activation of Trf3 expression and markedly delays
the muscle differentiation program. Thus, the Matn2-elicited
ECM signaling is needed to turn on Trf3, possibly by modifying
the composition of multiprotein Smad complexes formed with
other transcription factors. As the Trf3–Taf3 complex is known to
activate MyoD and to cause a global switch towards terminal
differentiation (Deato and Tjian, 2007; Deato et al., 2008), this
complex might mediate the Matn2-dependent upregulation of
MRF and muscle-specific genes in myoblasts (Fig. 8E).
Whereas the loose ECM surrounding myoblasts favors growth
factor signaling, the highly organized ECM of polynucleated
myotubes and myofibers rather provides a reservoir, releasing
growth factors upon damage (Fig. 8E). Matn2 might contribute to
cell adhesion by its interaction with integrins and ECM proteins,
such as collagens, fibrillins, laminin–nidogen complex and
fibronectin (Piecha et al., 2002; Mann et al., 2007; Klatt et al.,
2011). Working as an adaptor protein in the ECM, Matn2 might
directly or indirectly modulate TGF-b/BMP/Smad and other
signaling pathways through its interaction with fibronectin and
fibrillin. For instance, TGF-b family members are stored in latent
fibronectin- or fibrillin-bound structures in the ECM, and their
activation requires integrin binding and contractile forces
(Massague´, 2012). Matn2 deficiency also impaired p42 (Erk2)
phosphorylation that was implicated in myoblast fusion (Knight
and Kothary, 2011). However, further studies are required to fully
understand how the extracellular Matn2-elicited signals are
transduced to the cell nucleus.
Our model is in line with previous observations that TGF-b1
acts to inhibit myoblast differentiation (Schabort et al., 2009). It
also incorporates the finding that TGF-b1 opposes BMP signaling
and Matn2 expression, thus preventing the onset of a positive-
feedback loop whereby Matn2 and Nfix activate the expression of
one another (Fig. 8E). This positive-feedback loop might ensure
that sufficient levels of both Matn2 and Nfix are reached, such
that Nfix can, in turn, promote the initiation of the muscle-
specific gene expression program driven by further positive
autoregulatory loops formed by MyoD, Myog and p21 (Halevy
et al., 1995; Walsh and Perlman, 1997; Aziz et al., 2010). This
regulatory cascade fits well with prior observations of the
concomitant induction of MRF genes (MyoD, Myog, Mef2a) and
fetal muscle genes (Myh7) by forced Nfix expression in
embryonic myotubes and in differentiating C2 cells (Biressi
et al., 2007; Messina et al., 2010).
By controlling the expression of regulatory and ECM target
genes, Nfix can increase MyoD-dependent muscle-specific gene
expression (Aziz et al., 2010). Whether Nfix can directly control
the MyoD, Myog and/or p21 genes, and whether a feedback loop
also occurs between these regulatory intermediates, remains to be
established. However, this would be consistent with prior reports of
Nfi-binding sites in the Myog and p21 promoters (Johanson et al.,
1999; Ouellet et al., 2006), and with the finding that Nfi species can
act as a cofactor in muscle-specific transcription (Funk and Wright,
1992; Messina et al., 2010). Our interpretation of a regulatory
interplay between Nfix and cell cycle inhibitors, such as p21, is
also supported by a previously described role of Nfix in the
regulation of mitogenic pathways in other cell types (Nebl et al.,
1994). Our conclusions are also in line with prior observations of
regulatory relationships between TGF-b and other Nfi species
(Plasari et al., 2009; Plasari et al., 2010) and of BMP7 and Matn2
(Ichikawa et al., 2008) to control the timing of skin-wound healing.
In keeping with these findings, we observed severe wound-healing
defects in Matn22/2 mice on a C57BL/6 genetic background (F.
Dea´k and I. Kiss, data not shown). Our results provide evidence for
a molecular mechanism whereby TGF-b1-mediated regulation of
Matn2 might concomitantly control NFI expression.
Finally, our model provides a mechanistic explanation for the
transient activation of Matn2, MyoD and Myog during myogenic
differentiation. As MyoD expression is turned on in response to
increased expression of Matn2 and possibly also of Nfix, a
negative-feedback loop can be established whereby MyoD,
overcoming the effect of Nfix, will block Matn2 expression at late
stages of differentiation (Fig. 8E). This is accompanied by the
concomitant repression of Matn2, Nfix and MyoD, whereas the
expression of MyoD targets and downstream regulators of
myogenesis, such as Myog, persists until later stages, when
Fig. 7. Mild muscular dystrophy and delayed tibialis anterior muscle
regeneration in Matn22/2 mice. (A–F) Tibialis anterior regeneration was
quantified at the indicated days after notexin injection in wild-type (WT,
closed bars) andMatn22/2 (KO, open bars) mice. (A) Weight changes during
regeneration (n53–6). The CSA frequency distribution (B) and average CSA
(C) (300–400 myofibers/muscle, n53). (D) Quantification of split myofibers
on day 28 post-injury. The ratio of centrally nucleated versus all myofibers of
untreated tibialis anterior (E, left) and the ratio of non-peripheral versus all
myonuclei of untreated (E, right) and regenerating (F) adult tibialis anterior
are shown (2000 myonuclei/animal, n53). (G) Prolonged proliferation in
Matn2-deficient regenerating muscles was revealed by Lama2/desmin, Ki67/
Lama2 and Ki67/MyoD immunofluorescence. Arrowheads point to
Ki67+MyoD+ cells. (H) Quantification of Ki67+ versus all nuclei and
Ki67+MyoD+ nuclei within the MyoD+ nuclei population (10,000–30,000
nuclei/animal group, n53). (I) Double immunofluorescence indicates
transient Matn2 upregulation between days 3–7 around desmin-positive
myoblasts and myotubes. In Matn2-deficient mice, the numerous myoblasts
still detected inside the basement membrane of regenerating myofibers on
days 5 and 7 post-injury indicate delayed regeneration, whereas the
enrichment of degenerating and regenerating myofibers on days 14 and 28
shows mild dystrophy. The outlined area is shown as single-channel images
to the right of the main image. All quantitative data represent the
mean6s.e.m.; *P,0.05, **P,0.01, *** P,0.01.
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Fig. 8. The effect of Matn2 on marker gene expression during myoblast differentiation. (A) Impaired regeneration at day 28 in Matn22/2 mice. Necrotic
myofibers accumulate, which attracts numerous CD45-positive inflammatory cells (arrow), leading to increased fibronectin and collagen-3 deposition (magnified
insets). (B) QRT-PCR analysis of marker gene expression in ex vivo differentiating myoblast cultures derived from Matn22/2 and Matn2+/+ newborn mice,
performed using the SybrGreen protocol. Results show themean6s.e.m. (C) Immunoblot analysis of integrin a5 in limbs of E16.5 embryos and in wild-type (WT) and
Matn22/2 (KO) primary myoblast cultures. (D) FAK detection by immunoblotting in myoblast cultures differentiating ex vivo. For C and D, the proteins were quantified
by densitometry. (E) A model of myoblast differentiation. Regulatory interactions linking Matn2 expression to myoblast differentiation are illustrated schematically.
Red arrows indicate activation processes affected directly or indirectly by Matn2 signaling. BM, basement membrane; Fn, fibronectin.
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components of terminally differentiated myofibers, such as Myh1,
become expressed. The involvement of MRFs in Matn2 regulation is
supported by recent online reports of chromatin immunoprecipitation
data from the ENCODE consortium that reveal a possible binding of
MyoD to the Matn2 promoter in C2 myoblasts and increased
promoter occupancy by Myog in C2 myocytes.
In the absence of Matn2, BMP signaling alone or in
combination with signaling by other ECM proteins might also
activate MyoD and the myogenic regulatory program, but less
efficiently and more slowly than upon Trf3 induction in the
presence of Matn2 (Fig. 8E, black arrows). This can explain why
Matn2 deficiency only delays myogenic differentiation, causing
mild dystrophy, but does not block muscle differentiation or
regeneration in transgenic mice, as Matn22/2 mice develop
without obvious abnormalities (Ma´te´s et al., 2004). No deficiency
in embryonic or fetal muscle development was observed by light
microscopy. However, we recently observed that Matn22/2 mice
display an increased susceptibility to diethylnitrosamine-induced
hepatocarcinogenesis (Fulla´r et al., 2014) and wound-healing
defects with variable severity depending on the genetic
background (F. Dea´k and I. Kiss, data not shown). Muscles of
Smad2/2 mice also showed a mild myopathy, but denervation
caused a dramatic atrophy (Sartori et al., 2013).
Overall, this work identifies Matn2 as an important ECM protein
required for proper and timely myogenic differentiation and
skeletal muscle regeneration. As TSCs induce and guide the
sprouting of nerves at NMJs (Son et al., 1996), the Matn2-rich
matrix produced by TSCs at NMJs possibly also facilitates the
reinnervation process. Matn2 likely contributes to a broad range of
repair processes, as it is expressed in a variety of committed
proliferating cell types and it functions in regenerative processes of
the liver (Szabo´ et al., 2007), skin (Ichikawa et al., 2008) and
peripheral nerves (Malin et al., 2009). These data together support
the hypothesis that Matn2 controls ECM–cell communication, and
that it can thereby regulate the early steps of cell differentiation and
repair processes of various tissues, in concert with NFI
transcription factors and TGF-b signaling pathways.
Accordingly, other members of the NFI family have been
implicated in other regenerative processes of adult tissue in the
context of TGF-b signaling. For instance, Nfic has been
implicated in tooth morphogenesis, skin-wound healing and
the onset of the follicle cycle leading to hair regeneration (Lee
et al., 2009; Plasari et al., 2009; Plasari et al., 2010). An NFIC
isoform was shown to harbor a TGF-b-responsive domain, and
NFI-binding sites acting as TGF-b-responsive elements have
been reported in several other ECM genes (Alevizopoulos et al.,
1995; Alonso et al., 1996; Iozzo et al., 1997). Collectively, these
findings link the NFI transcription factors and ECM target
proteins, such as Matn2, to the regulation of the onset of a
variety of adult tissue regeneration processes.
MATERIALS AND METHODS
Animal treatment
For this study, 3-month-old Wistar rats were anesthetized by
intraperitoneal injection of 4% chloral hydrate (10 ml/g). Muscle
necrosis was induced by intramuscular injection of 20 mg of notexin,
as described previously (Za´dor et al., 1996). The animals were killed by
an overdose of sodium pentobarbital. The entire soleus muscles of control
or notexin-treated legs were removed, weighed and stored at 280 C˚ after
freezing in isopentane cooled by liquid nitrogen.
The generation of Matn22/2 mice has been reported previously (Ma´te´s
et al., 2004). Muscle regeneration was induced in 10-week-old Matn22/2
mice and wild-type littermates by injecting 0.3 mg (60 ml) of notexin
(Sigma-Aldrich) into the tibialis anterior muscle. All animal treatments
were conducted in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and under the
approval of the Animal Health Care and Control Institute, Csongra´d
County, Hungary.
Cell culture
C2 myoblast cell line clone 7 (Yaffe and Saxel, 1977; Montarras et al.,
1996) and primary myoblasts, which were prepared from the thigh
muscle of neonatal mice as described previously (Springer et al., 1997),
were propagated in growth medium containing 20% fetal bovine serum
(FBS, Gibco) (Halevy et al., 1995). Differentiation was induced by
switching the 80% confluent cultures to differentiation medium
containing 2% horse serum, and this was defined as day 0. The
cultures were photographed with an Olympus Cell R microscope. In
some experiments, 5 ng/ml TGF-b1 (Immunotools) was added to
differentiation medium on day 0 and was changed daily.
Differentiation experiments were repeated at least three times.
Table 1. Comparison of the expression levels of marker genes in fetal limbs and myoblast cultures from Matn22/2 versus wild-type
mice by QRT-PCR
E16.5 fetal limbs Myoblast cultures
Gene symbol Average ratioa log2 (DCt) P value Fold change Average ratioa log2 (DCt) P value Fold change
Nfia 23.5560.61 7.2E209*** 211.71 20.5560.07 0.02* 21.46
Nfib 26.0562.09 3.73E205*** 266.26 20.4060.37 0.34 21.31
Nfic +0.0160.34 0.94 +0.99 20.9760.24 0.004** 21.95
Nfix 21.3560.68 0.001*** 22.55 20.5760.15 0.02* 21.48
MyoD 20.5360.33 0.006** 21.44 21.3960.21 0.0004*** 22.63
MyoG 21.5960.29 0.0006*** 23.20 21.426018 0.00001*** 22.67
Itga5 +0.2460.34 0.18 +1.17 20.9060.30 0.01** 21.87
Bmp7 21.8760.46 7.66E207*** 23.64 21.8460.71 0.002** 23.59
Fak 20.9360.69 0.01** 21.90 21.2760.42 0.02* 22.42
Matn2 (ex1ex2) no product in Matn22/2 embryos no product in Matn22/2 culture
Trf3 28.5061.19 3.87E210*** 2360.79 22.3860.46 0.0009*** 25.21
Taf3 20.6460.56 0.04* 21.56 21.3260.43 0.03* 22.49
Myh1 21.6960.55 0.03* 23.20 20.6960.25 0.05* 21.62
Eno 22.4060.54 0.0007*** 25.27 21.2160.16 0.002** 22.31
Ckm +0.4660.12 0.4 +1.37 20.8860.16 0.006** 21.84
p21 +0.4360.33 0.2 +1.30 20.8260.13 0.0014** 21.76
aMean6s.e.m., n59. Ct values were normalized to the Ct value of the invariant Rps18. *P,0.05, **P,0.01, ***P,0.001 (two-sample t-test).
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Histology, immunohistochemistry and immunofluorescence
The average CSA and fiber-size distributions were determined using
the Digimizer software (MedCalc Software, Mariakerke, Belgium).
Immunohistochemistry was performed as described previously (Piecha
et al., 1999). Primary and secondary antibodies used for
immunofluorescence of acetone-fixed 10-mm cryosections and cells
grown on coverslips are listed in supplementary material Table S1.
Nonspecific binding of the antibodies was blocked with 10% proper
normal serum. Nuclei were stained with DAPI. NMJs were detected
with tetramethylrhodamine a-bungarotoxin (Invitrogen, 1:200). The
specimens were mounted with fluorescent mounting medium (Dako),
viewed with a Nikon Eclipse E600 microscope equipped with
epifluorescence and photographed with a Spot RT Slider camera. The
images were processed using SPOT software (version 4.0.9 for Windows;
Diagnostic Instruments). Figures were created with Adobe Photoshop 8.0
and CorelDraw X4 softwares.
Protein extraction and immunoblot analysis
The myoblast cell layer was extracted in ice-cold buffer containing
20 mM Tris-HCl pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X-100 and protease inhibitors. After centrifugation at 10,000 g for
10 min at 4 C˚, supernatant proteins were separated by SDS-PAGE,
blotted and developed as described previously (Piecha et al., 1999).
Primary and HRP-conjugated secondary antisera are listed in
supplementary material Table S1. Images were quantified with the
Quantity One-4.2.3. program (BioRad). Experiments were repeated at
least three times.
RNA analysis
Pooled total RNA was isolated from rat soleus muscles (n53) and used
for northern analysis as described previously (Dea´k et al., 1997), using
gene-specific cDNA fragments (supplementary material Table S2). For
QRT-PCR, pooled total RNA was isolated from three cultures of
differentiating C2 cell lines, three primary myoblast cultures grown
either in growth medium or differentiating ex vivo in differentiation
medium and also from E16.5 fetal limbs. QRT-PCR was performed with
the SYBR green protocol, as described previously (Nagy et al., 2011).
TaqMan probe sets and the TaqMan Gene Expression Master Mix
(Applied Biosystems) were used with the following program: 15 min at
95 C˚; 45 cycles of 95 C˚ for 15 s and 60 C˚ for 1 min. Gene-specific
primers and TaqMan probe sets are listed in supplementary material
Table S2. Individual threshold cycle (Ct) values were normalized either
to the average Ct values of three internal control genes (Hprt, Rps18 and
CycloAb) (SYBR green) or to the Ct values of Hprt (TaqMan probe).
Relative gene expression levels are presented as log2 ratios or fold
values.
Silencing and rescuing Matn2 expression
We designed shRNA targeting Matn2 using the program RNAi explorer
(Fig. 4D). Oligonucleotides were annealed, phosphorylated and inserted
into the pFP/Neo-H1 vector (Kaufman et al., 2005), following
recommendations for the pSUPER system to generate the derivative
KD2639. A total of 16105 C2 myoblasts were co-transfected in growth
medium with 500 ng of purified KD2639 or pFP/Neo-H1 control DNA
and 50 ng of pFvFP helper vector using ExGene 500 (Fermentas). At
24 h after plating, the cells were seeded into 10-cm dishes for a 2-week
selection in growth medium containing 500 mg/ml G418 (Cambrex), and
stably transfected Matn2-silenced cell lines were established from G418-
resistant single colonies.
To rescue Matn2 silencing, we modified the cDNA encoding full-
length mouse Matn2 by mutating the sequence targeted by the shRNA but
preserving its protein coding capacity (Fig. 4D). The modified cDNA
was inserted into the pCEP-Pu expression vector and the recombinant
plasmid was introduced into the sh3 cell line silenced for Matn2. Clones
that were resistant to 1 mg/ml puromycin were pooled. Independent
control (Ctrl), silenced (sh3, sh4, and sh7) cell lines and rescued (sh3-
res2) cultures were tested for myogenic differentiation and marker gene
expression in at least three independent experiments.
Cell proliferation and differentiation assays
The MTS assay for mitochondrial function was performed with the
CellTiter96 AQueous One solution cell proliferation kit (Promega),
according to the manufacturer’s protocol. For the evaluation of
differentiation, myoblast cultures were stained for sarcomeric a-
actinin and nuclei (DAPI). In randomly chosen microscope fields
containing a total of 3000–4000 nuclei, a-actinin-positive myoblasts
were counted. Primary myotube frequency was calculated as the
number of myotubes containing ,3 nuclei divided by the total number
of cells in a given microscope field. The fusion index was defined as
the number of myotubes harboring §3 nuclei divided by the
total number of cells. The differentiation index was defined as the
number of myotube nuclei divided by the total number of nuclei.
Data represent the mean6s.e.m. from three to five independent
experiments.
Alternative promoter analysis
1-ml aliquots of total RNA samples treated with RNase-free
DNase (Roche Molecular Biochemicals) were subjected to oligo(dT)-
primed first-strand cDNA synthesis, followed by PCR using promoter-
specific primer pairs (Fig. 6A), as described previously (Ma´te´s et al.,
2002).
EMSA
The program Jaspar was used to search for putative NFI and MyoD
recognition sequences in the Matn2 promoter and to synthesize double-
stranded oligonucleotides (Fig. 6D). Constructs encoding GST–CTF1, an
isoform of the human NFIC (Alevizopoulos et al., 1995) and GST–MyoD
(Biesiada et al., 1999) were expressed, and the proteins were purified
essentially as described previously (Nagy et al., 2011). 20–30 fmol of
end-labeled wild-type and mutant DNA probes were incubated with 0.6–
2.5 mg of GST or GST–MyoD in the presence of 300 ng of poly(dI-
dC)Npoly(dI-dC), as described previously (Biesiada et al., 1999). To test
NFI binding, the probes were incubated with 1.25–2.5 mg of GST–CTF1
or with 1.25 mg each of GST-fused CTF1 and MyoD, as described
previously (Szabo´ et al., 1995), and separated by electrophoresis on a pre-
run 5% polyacrylamide gel.
Transient expression assay
Pd(2342)Luc was constructed by inserting the 2342/+60 Pd fragment
into the PvuII/PstI site of the pGL3-Basic Vector (Promega). Derivatives
carrying point mutations in the MyoD motif near the start site (Mdm1,
Pd212/+15) in the NFI motif (Nfm1) or in both the NFI and MyoD
consensus sequences (NfMdm1) of the Nfi/MyoD composite element
Pd2135/2107 were made using the PCR based QuikChangeTM Site-
Directed Mutagenesis kit (Stratagene).
C2 myoblasts (cultured in growth medium) and COS-7 cells were
transfected with 3–5 mg of wild-type and mutant reporters in six-well
plates using ExGene 500 (Fermentas) or the calcium phosphate
coprecipitation method, respectively, and luciferase activities were
measured, as described previously (Nagy et al., 2011). Forced
expression assays were performed with 3–5 mg of reporters and
increasing amounts of expression plasmids for MyoD (pFMyoD, a gift
from Vittorio Sartorelli) or mouse NFI proteins (pFNfia, pFNfib,
pFNfic and pFNfix). The latter plasmids harbour the coding sequences
of mouse NFI genes (Chaudhry et al., 1998) in pcDNA59UT-FLAG, as
described previously (Nagy et al., 2011). The effect of 50 ng/ml BMP7
(ImmunoTools) was tested in Opti-MEMH (Gibco). Transfection
mixtures were adjusted with the appropriate empty vectors to the
same amount of total DNA. Luciferase activities were expressed as
fold values relative to that for Pd(2342)Luc. Results are the
mean6s.e.m. from at least three independent experiments.
Statistical analysis
Data are presented as the mean6s.e.m. Statistical significance was
determined using a one-way analysis of variance (ANOVA) with KyPlot
version 2.0 beta 15; *P,0.05, **P,0.01, ***P,0.001.
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Fig. S1. Double immunofluorescence staining for Matn2 and other markers during rat soleus 
regeneration. (A) Strong Matn2 staining around nerve fibers visualized by peripherin (Per) staining in the 
untreated soleus. (B) Lack of Matn2 staining around granulocytes (g) expressing myeloperoxidase (MPO) 
two days postinjury. (C) Deposition of Matn2 around MyoD- and Myog-expressing cells (arrowhead) on 
day 2 of regeneration. (D) Matn2 shows partial colocalization with fibronectin (Fn) and collagen-1 (Col1) 
in the endomysium and perimysium of untreated and regenerating muscles. The colocalization of Matn2 
and fibronectin is most evident on day 2 after treatment and around blood vessels. All three ECM proteins 
exhibit broader expression domain on days 2 and 7 of muscle regeneration compared to that of the 
untreated control muscle. Other symbols are as in Fig. 2. 
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Fig. S2. Delayed myogenic differentiation and marker gene expression in various Matn2-silenced C2 
cell lines. Comparison of phase-contrast microscopy (A), immunofluorescence (B) and marker mRNA 
levels (C) of parallel cultures of the Ctrl and silenced myoblast cell lines upon differentiation in DM. (A) 
Arrowheads point at multinucleated myotubes. (B) Double immunofluorescence staining of the cultures 
for Matn2 (red) and sarcomeric α-actinin (green). Note that the α-actinin-positive myotubes appear later, 
they are narrower and mononuclear in the Matn2-silenced cultures. (C) Marker gene expression measured 
by QRT-PCR analysis using the SYBR green protocol is plotted in fold relative to three internal control 
genes to illustrate reproducibility. 
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Fig. S3. Marker gene expression changes in differentiating Matn2-silenced and rescued myoblasts 
cultures. (A) Expression of Nfix and the early and late myogenic marker genes depends on the rescued 
Matn2 level. QRT-PCR analysis performed with TaqMan probes from another differentiation experiment 
of control, silenced and rescued myoblasts in DM is shown for comparison with Fig. 4I. Marker mRNA 
levels are presented as fold values relative to that of the HPRT mRNA. (B) Level of pSmads and pFAK in 
the sh3, Ctrl and rescued sh3-res2 myoblast cultures and quantification of the results. (C) Absence of 
Matn2 affects P42/P44 phosphorylation in muscles of newborn mice (left panel) and in C2 myoblast 
cultures on day 2 of differentiation (right panel).  
Journal of Cell Science | Supplementary Material
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Fig. S4. Matn2 distribution in mouse skeletal muscle and notexin-induced TA regeneration. Matn2 
immunohistochemistry (A) and immunofluorescence (B-E) in transverse cryosections of forelimb (A-C) 
and skull (D-E) muscles of newborn (A,B,D) and adult (C,E) mice. Deposition is seen in the epimysium 
(epm), perimysium, endomysium, nerves, MTJ and tendon (te). The signal intensities are moderate in the 
endomysium of muscle fibers in newborn animals and decreased further in adults. Immunoblot detection 
of Matn2 (F) and Coomassie Brilliant Blue staining (G) of muscle extracts of 15-day-old (y) and adult (a) 
mouse thigh. Without sample reduction, Matn2 is resolved predominantly as a trimer, but dimer, monomer 
and proteolytically processed forms are also visible in young mice (F). (H,I) H&E staining of TA cross 
sections from WT and Matn2−/− mice during regeneration (H) and at the age of 10 months (I). Arrowheads 
denote non-peripheral nuclei in untreated Matn2−/− mice, black arrows point to split fibers. In addition to 
fiber splitting, necrotic fibers with invading cells (white arrow) and increased ECM deposition (yellow 
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arrow) also occur in some areas of Matn2-deficient muscles on day 28 of regeneration (H). (J) Double 
staining of 10-month-old mouse TA shows collagen-1 and fibronectin deposition in connective tissues, 
especially around nerves and blood vessels, without signs of increased fibrosis in Matn2−/− mice. Other 
symbols are as in Figs. 1-3. 
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Table S1. Primary and secondary antibodies used in the study 
 
Primary antibodies used in the study 
 
Target  Species Manufacturer   Dilution for 
    or reference          IF and IHC immunoblot 
matrilin-2  rabbit  Piecha et al., 1999  1:100  1:3000 
matrilin-2 goat  R&D, AF3234   1:200 
laminin  rabbit  DAKO, Z0097   1:400 
laminin α2  rabbit  Ringelmann et al., 1999 1:1000 
laminin α2  rat clone 4H8 Schuler and Sorokin, 1995 undiluted 
fibronectin rabbit  Sigma, F3648   1:200 
Ki67   rat  DakoCytomation, M7249  1:100 
peripherin rabbit  Chemicon   1:100 
MyoD1  mouse  Chemicon   1:30 
MyoD (C20) rabbit  Santa Cruz, sc-304  1:50 
myogenin mouse F5D Thermo Scientific  1:30 
desmin  rabbit  Euro-Diagnostica  1:100 
desmin  mouse  DakoCytomation, M0760 1:200  1:1000 
sarcomeric α-actinin, mouse SIGMA, A7811  1:400 
vinculin mouse  SIGMA, V9131  1:400 
paxillin  mouse  SIGMA, P1093   1:400 
mouse collagen I, rabbit Millipore, AB765P  1:200  
collagen 3 goat  SouthernBiotech, 1330-01 1:200 
GFAP-Alexa488, mouse GA5,eBioscience 53-9892  1:500 
CD45  rat clone 30G12 Ralph and Berridge, 1984 undiluted 
myeloperoxidase rabbit  NeoMarkers   1:30 
sarcomeric α-actin, mouse DakoCytomation, M0874   1:1000  
Smad4   mouse  Santa Cruz, Sc-7966    1:1000 
p21 (M-19) rabbit   Santa Cruz, Sc-471    1:200 
β-actin   mouse   SIGMA, A2228     1:5000 
integrin a5  rabbit   Chemicon, AB1949    1:500 
FAK (c-20)  rabbit   Santa Cruz, sc-558    1:1000 
p-FAK (Tyr 397) rabbit  Santa Cruz, sc-11765-R   1:1000 
p-Smad2 rabbit   Invitrogen, 44-244G    1:1000 
p-Smad1/5/8 rabbit  Cell Signaling Technology, 9511  1:1000  
P44/42   rabbit   Cell Signaling Technology, 9102  1:1000  
pP44/42  rabbit mAb Cell Signaling Technology, 4370  1:1000  
 
Secondary antibodies used in the study 
 
Target          Species Conjugated       Manufacturer  Dilution for 
             IF and IHC     immunoblot 
rabbit IgG donkey    Alexa488 Molecular Probes  1:500 
goat IgG   donkey    Cy3  Jackson Immunoresearch 1:400 
goat IgG   donkey    Cy2  Jackson Immunoresearch 1:400 
mouse IgG  donkey    Cy3  Jackson Immunoresearch 1:400 
mouse IgG  donkey    DyLight 488 Jackson Immunoresearch 1:100 
rat IgG   donkey    Cy3  Jackson Immunoresearch 1:400 
rabbit IgG   goat    HRP  Sigma, A6154   1:100  1:5000 
mouse IgG   goat    HRP  Sigma, A9309     1:5000 
goat IgG   rabbit    HRP  DakoCytomation, P0449   1:5000 
 
Ralph SJ, Berridge MV (1984) J. Immunol. 132:2510-2514 
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Table S2. Primers used for amplification of hybridization probes and QRT-PCR 
 
Symbol     Acc. No. Forward sequence  Reverse sequence 
 
Matn2 a  XM_216941  cctaccccaacggcataca  tgtgtgaacagtggcgaatc 
MyoD a  NM_176079  ggttgagcgagaagcagga  gtagtaggcggcgtcgtag 
Myog a  NM_017115  gacctgatggagctgtat   agacaatctcagttgggc 
Gapdh a  NR_033630  ccagccccagcatcaaaggt  caactttggcatcgtggaag 
Matn2 b  XM_216941  gaggtggagagggctgtcaag  gcaatgttgagggcatattgg 
MyoD b  NM_176079  ggacagccggtgtgcatt  cactccggaaccccaacag 
Myog b  NM_017115  ggagaagcgcaggctcaag  ttgagcagggtgctcctctt 
Fak b  NM_013081  agtgacgtgtggatgtttgc  atccgttcttcttgctgcac 
Matn2 c  NM_016762  gaggtggagagggctgtcaag  gcaatgttgagggcatattgg 
Matn2 (ex1ex2) c NM_016762 ctgctcccctgtctctcttc   cccaccaacatcttctccat  
MyoD c  M84918    cgacaccgcctactacagtg  tatgctggacaggcagtcg 
Myog c  NM_031189  ccttgctcagctccctca   tgggagttgcattcactgg 
Myh1 c  NM_030679  aatcaaaggtcaaggcctacaa  gaatttggccaggttgacat 
Trf3 c  AY457924  tcatctttagctctgggaaagtg  cagccgagactcctcttcac 
Taf3 c  NM_027748  ctgccatcggtactctgaact  agttcatgcagattaactcccata 
p21 c  NM_007669  tccacagcgatatccagaca  ggacatcaccaggattggac 
Mstn c  NM_010834  tggccatgatcttgctgtaa  ccttgacttctaaaaagggattca 
p53 c  NM_011640  acgcttctccgaagactgg  agggagctcgaggctgata 
Lama2 c  NM_008481  tcaaccatgtgcttgtcctc  caatacacaagaggggctgaa 
Col6a1 c  NM_009933  gacatccagggctccaaa  aggtgtcgagcacgaagaat 
Sdc4 c  NM_011521  cccttccctgaagtgattga  agttccttgggctctgagg 
Fn c  NM_010233  cggagagagtgcccctacta  cgatattggtgaatcgcaga 
Col1a1 c  NM_007742  catgttcagctttgtggacct  gcagctgacttcagggatgt 
Fak c  AB030035  agtgacgtgtggatgtttgc  atccgttcttcttgctgcac 
Itga5 c  NM_008402  ggtgtggatcgagctgtctt  caaggccagcatttacagtg 
Nfia c  NM_010905  ggaactcgatttatatttggcatac  ctggctgggactttcagatt 
Nfib c  NM_008687  ccggaatacctggagtcg  gaaatggcaacggtgagg 
Nfic c  NM_026756  catcgcggtacacagtgg  ggccgtatgggggaagta 
Nfix c  NM_001081981    tgactcctccatcaccttca  gatccgatgctgacaaacc 
Eno c  X62667.1  ctttgcacccaacatcctg  gcctggatggctgtctttag 
Ckm c  NM_007710.2  cagcacagacagacactcagg   gaacttgttgtgggtgttgc 
Rps18 b, c  NM_011296  tttgcgagtactcaacaccaa  ttcctcaacaccacatgagc 
Hprt b, c  NM_013556  tcctcctcagaccgctttt   cctggttcatcatcgctaatc 
CycloAb b, c NM_008907  cacaaacggttcccagtttt  ttcccaaagaccacatgctt 
Matn2  NM_016762.2     Mm01166023_m1 d 
MyoD1  NM_010866.2     Mm00440387_m1 d 
Myog  NM_031189.2     Mm00446194_m1 d 
p21  NM_007669.4     Mm01303209_m1 d 
Myh1  NM_030679.1     Mm01332489_m1 d 
Mstn  NM_010834.2     Mm00440328_m1 d 
Nfia  NM_001122952.1     Mm00447981_m1 d 
Nfix  NM_001081982.1     Mm00477796_m1 d 
Hprt  NM_013556.2     Mm00446968_m1 d 
 
a Primers used for amplification of cDNA probes in Northern hybridization 
b Primers used in SYBR green protocol for rat samples 
c Primers used in SYBR green protocol for mouse samples  
d Applied Biosystems TaqMan probe sets 
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